EpiVax Inc - Company Profile
Powered by 
All the sales intelligence you need on EpiVax Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how EpiVax Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with EpiVax Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
View up-to-date information on EpiVax Inc patents, including inventor and filing insights.
Patent Trends
| Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
|---|---|---|---|---|
| EP4126907A1 | Application | TREPITOPKONSTRUKTE ZUR VORBEUGUNG UND BEHANDLUNG VON TYP-1-DIABETES | A61K38/00; A61P3/10; C07K14/7051; C07K2319/31 | February 08, 2023 |
| EP4126901A1 | Application | REGULATORISCHE T-ZELLEN-EPITOPE | A61K2035/122; A61K2039/55544; A61K2039/577; A61K35/17; A61K38/00; A61K39/0008; A61K39/001; A61K39/12; A61P37/00; C07K14/70503; C07K7/08; C12N2510/00; C12N2760/16034; C12N5/0637 | February 08, 2023 |
| WO2023004307A1 | Application | T CELL EPITOPES AND RELATED COMPOSITIONS USEFUL IN THE PREVENTION AND TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | January 26, 2023 | |
| EP4103232A1 | Application | REGULATORISCHE T-ZELL-EPITOPE UND DETOLERIERTE SARS-COV-2-ANTIGENE | A61K39/12; A61P11/00; A61P31/14; C07K14/005; C12N2770/20022; C12N2770/20034 | December 21, 2022 |
| EP4103233A1 | Application | T-ZELL-EPITOPE UND ZUGEHÖRIGE ZUSAMMENSETZUNGEN ZUR VORBEUGUNG, DIAGNOSE UND BEHANDLUNG VON COVID-19 | A61K39/12; A61P11/00; A61P31/14; C07K14/005; C12N2770/20022; C12N2770/20034 | December 21, 2022 |
Top Inventors by Filings (Count by publication)
| Name | Count |
|---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer